Capricor Therapeutics (CAPR) Receivables - Net (2012 - 2025)

Capricor Therapeutics' Receivables - Net history runs 13 years deep, the most recent figure standing at $59167.0 for Q3 2025.

• On a quarterly basis, Receivables - Net fell 85.56% year-over-year to $59167.0 in Q3 2025; TTM through Sep 2025 was $59167.0, a 85.56% decrease from a year earlier, with the FY2025 full-year figure at $59167.0, down 99.43% from the prior year.
• Receivables - Net declined to $59167.0 in Q3 2025 per CAPR's latest filing, from $59509.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $10.4 million in Q4 2024 and bottomed at $59167.0 in Q3 2025.
• The 5-year median for Receivables - Net is $409682.0 (2024), against an average of $1.5 million.
• Across the five-year window, Receivables - Net surged 1726.22% in 2023 and sank 85.56% in 2025, its largest moves.
• Year by year, Receivables - Net stood at $391750.0 in 2021, then soared by 39.78% to $547580.0 in 2022, then jumped by 1726.22% to $10.0 million in 2023, then grew by 3.68% to $10.4 million in 2024, then sank by 99.43% to $59167.0 in 2025.
• Per Business Quant, the three latest CAPR Receivables - Net figures stand at $59167.0 (Q3 2025), $59509.0 (Q2 2025), and $59834.0 (Q1 2025).